nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial
|
Martin, Janet |
|
1997 |
40 |
3 |
p. 189-201 |
artikel |
2 |
Antiestrogenic activities of alternate-substituted polychlorinated dibenzofurans in MCF-7 human breast cancer cells
|
Sun, Gulan |
|
1997 |
40 |
3 |
p. 239-244 |
artikel |
3 |
Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248)
|
Mosure, Kathleen W. |
|
1997 |
40 |
3 |
p. 251-258 |
artikel |
4 |
Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice
|
Stewart, Clinton F. |
|
1997 |
40 |
3 |
p. 259-265 |
artikel |
5 |
Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer
|
Sugimachi, Keizo |
|
1997 |
40 |
3 |
p. 233-238 |
artikel |
6 |
Effect of single and multiple administration of an O 6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model
|
Wedge, Stephen R. |
|
1997 |
40 |
3 |
p. 266-272 |
artikel |
7 |
Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis
|
Bellmunt, J. |
|
1997 |
40 |
3 |
p. 273-276 |
artikel |
8 |
Human tumor models in the severe combined immune deficient (scid) mouse
|
Paine-Murrieta, Gillian D. |
|
1997 |
40 |
3 |
p. 209-214 |
artikel |
9 |
Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics
|
Rekha, Ganaganur K. |
|
1997 |
40 |
3 |
p. 215-224 |
artikel |
10 |
Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease
|
Morgan, Denis J. |
|
1997 |
40 |
3 |
p. 202-208 |
artikel |
11 |
Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma
|
Zalupski, Mark M. |
|
1997 |
40 |
3 |
p. 225-227 |
artikel |
12 |
Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration
|
Zhan, Zhirong |
|
1997 |
40 |
3 |
p. 245-250 |
artikel |
13 |
Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents
|
Sackett, Dan L. |
|
1997 |
40 |
3 |
p. 228-232 |
artikel |